blast crisis

Summary

Summary: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.

Top Publications

  1. Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant. 2007;40:83-4 pubmed
  2. Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res. 2009;33:490-4 pubmed publisher
    ..Thus, in AML, the activity of IDO can be easily monitored, providing a tool for future clinical testing of IDO-blocking drugs...
  3. Pullarkat S, Vardiman J, Slovak M, Rao D, Rao N, Bedell V, et al. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res. 2008;32:1770-5 pubmed publisher
    ..either de novo or by transformation of a preexisting myelodysplastic or myeloproliferative process including blast crisis of chronic myeloid leukemia (CML)...
  4. Ito T, Kwon H, Zimdahl B, Congdon K, Blum J, Lento W, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466:765-8 pubmed publisher
    Chronic myelogenous leukaemia (CML) can progress from a slow growing chronic phase to an aggressive blast crisis phase, but the molecular basis of this transition remains poorly understood...
  5. Marega M, Piazza R, Pirola A, Redaelli S, Mogavero A, Iacobucci I, et al. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia. 2010;24:1445-9 pubmed publisher
    ..The molecular mechanisms leading from chronic phase (CP) to blast crisis (BC) are not understood...
  6. Ashur Fabian O, Adamsky K, Trakhtenbrot L, Cohen Y, Raanani P, Hardan I, et al. Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle. 2007;6:589-94 pubmed
    Chronic myelogenous leukemia (CML) is a stem cell disorder that eventually progresses to a blast crisis phase (BC) characterized by distorted apoptotic pathways...
  7. Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Med Hypotheses. 2008;70:128-36 pubmed
    ..During the accelerated phase and blast crisis, the population of CML cells and the fraction of immature cells rises sharply...
  8. Neering S, Bushnell T, Sozer S, Ashton J, Rossi R, Wang P, et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007;110:2578-85 pubmed
    ..Taken together, the system provides a powerful means by which the in vivo behavior of LSCs versus HSCs can be characterized and candidate treatment regimens can be optimized for maximal specificity toward primitive leukemia cells...
  9. Campiotti L, Grandi A, Biotti M, Ultori C, Solbiati F, Codari R, et al. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. Am J Hematol. 2007;82:231-3 pubmed
    We describe an extremely rare case of megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. The patient had a very high platelet count and developed an ischemic stroke with seizures...

More Information

Publications68

  1. Oehler V, Yeung K, Choi Y, Bumgarner R, Raftery A, Radich J. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009;114:3292-8 pubmed publisher
    ..identified 6 genes (NOB1, DDX47, IGSF2, LTB4R, SCARB1, and SLC25A3) that discriminated chronic phase (CP) from blast crisis (BC) CML. In CML, phase labels divide disease progression into discrete states...
  2. Neviani P, Santhanam R, Oaks J, Eiring A, Notari M, Blaser B, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117:2408-21 pubmed
    b>Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term ..
  3. Paquette R, Nicoll J, Chalukya M, Elashoff D, Shah N, Sawyers C, et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet. 2011;204:392-7 pubmed publisher
    ..1 (EVI1) translocations were evaluated in 42 consecutive chronic myeloid leukemia (CML) patients in myeloid blast crisis (MBC)...
  4. Nicolini F, Masszi T, Shen Z, Gallagher N, Jootar S, Powell B, et al. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53:907-14 pubmed publisher
    ..Reported here are the efficacy and safety data for patients in CML-AP (n = 181) or blast crisis (CML-BC) (n = 190; myeloid BC, 133; lymphoid BC, 50; unknown, seven) enrolled in an expanded access phase IIIb ..
  5. Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792-6 pubmed publisher
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  6. Mu H, Xie R, Shen Y, Jiang Y, Zeng Y. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene. Br J Biomed Sci. 2009;66:20-4 pubmed
    ..gene is investigated in peripheral blood from 30 healthy adults, 25 primary CML patients and 25 CML patients in blast crisis using the EvaGreen real-time reverse transcriptase polymerase chain reaction (RT-PCR)...
  7. Makishima H, Jankowska A, McDevitt M, O Keefe C, Dujardin S, Cazzolli H, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117:e198-206 pubmed publisher
    ..2 and 21q22.12 involved tumor associated genes NF1 and RUNX1, respectively. Our results indicate that CBL family, TET2, ASXL1, and IDH family mutations and additional cryptic karyotypic abnormalities can occur in advanced phase CML. ..
  8. Roche Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111:3735-41 pubmed publisher
    ..acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1...
  9. Al Shehri A, Al Seraihy A, Owaidah T, Belgaumi A. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2010;3:42-6 pubmed
    Patients with chronic myeloid leukemia (CML) infrequently present in blast crisis (BC). While most BC are of myeloid origin, megakaryocytic BC is rare, especially at the time of CML diagnosis...
  10. Carter B, Mak D, Shi Y, Schober W, Wang R, Konopleva M, et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006;5:2223-9 pubmed
    Patients with blast crisis (BC) CML frequently become resistant to Imatinib, a Bcr-Abl tyrosine kinase-targeting agent...
  11. Patel H, Gordon M. Abnormal centrosome-centriole cycle in chronic myeloid leukaemia?. Br J Haematol. 2009;146:408-17 pubmed publisher
    ..Primary cells from CML blast crisis (BC) patients exhibited a distinctive amorphous staining pattern of pericentrin compared to normal and CML ..
  12. Zhang W, Cortes J, Yao H, Zhang L, Reddy N, Jabbour E, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009;27:3642-9 pubmed publisher
    ..Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission...
  13. Phan C, Megat Baharuddin P, Chin L, Zakaria Z, Yegappan S, Sathar J, et al. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2008;180:60-4 pubmed
    ..CML is clinically characterized by three distinct phases: chronic, accelerated, and blast phase. Blast crisis is characterized by the rapid expansion of a population of differentiation arrested blast cells (myeloid or ..
  14. Xiao Jun H, Lan Ping X, Kai Yan L, Dai Hong L, Huan C, Wei H, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med. 2008;40:444-55 pubmed publisher
    ..Recently, we developed an effective method for haploidentical allo-HSCT achieving comparable outcomes to HLA-identical transplantation...
  15. Miyazaki K, Yamasaki N, Oda H, Kuwata T, Kanno Y, Miyazaki M, et al. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia. Blood. 2009;113:4702-10 pubmed publisher
    ..from p210BCR/ABL-transformed stem cells, which begins as indolent chronic phase (CP) but progresses into fatal blast crisis (BC)...
  16. Kim H, Jung C, Kim K, Ahn J, Kim W, Park K, et al. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. J Clin Oncol. 2006;24:4028-9 pubmed
  17. Uchida T, Kitaura J, Nakahara F, Togami K, Inoue D, Maehara A, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014;42:369-379.e3 pubmed publisher
    We have previously shown that elevated expression of Hairy enhancer of split 1 (Hes1) contributes to blast crisis transition in Bcr-Abl-positive chronic myelogenous leukemia...
  18. Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737-47 pubmed publisher
    b>Blast crisis (BC) remains the major challenge in the management of chronic myeloid leukemia (CML)...
  19. Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells. 2007;25:1114-8 pubmed
    ..myeloid leukemia (CML) progresses through three distinct clinical stages: chronic phase, accelerated phase, and blast crisis. The progression to accelerated phase and blast crisis is driven by activation of oncogenes, inactivation of ..
  20. Nagamachi A, Yamasaki N, Miyazaki K, Oda H, Miyazaki M, Honda Z, et al. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model. Cancer Sci. 2009;100:1219-26 pubmed publisher
    ..is a hematological malignancy that begins as indolent chronic phase (CP) but inevitably progresses to fatal blast crisis (BC)...
  21. Zhang J, Jin Z, Du Q, Li R, Yao F, Huang B, et al. Analysis of altered proteins related to blast crisis in chronic myeloid leukemia by proteomic study. Int J Lab Hematol. 2012;34:267-73 pubmed publisher
    Chromic myeloid leukemia (CML) blast crisis (BC) and imatinib (IM) resistance is a significant barrier to the effective treatment of the disease.
  22. Zhao L, Wang Y, Li G, Ma L, Xiong S, Weng X, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood. 2012;119:2873-82 pubmed publisher
    ..disorder status at the chronic phase of the disease, but progression from the chronic phase to blast crisis (BC) is believed to require additional mutations...
  23. Lim S, Saw T, Zhang M, Janes M, Nacro K, Hill J, et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013;110:E2298-307 pubmed publisher
    ..the oncogenic fusion protein BCR-ABL1 in chronic phase, but is resistant to treatment after it progresses to blast crisis (BC)...
  24. Strout M, Schatz D. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way. Cancer Cell. 2009;16:174-6 pubmed publisher
  25. Cortes J, Rousselot P, Kim D, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-13 pubmed
    The prognosis for patients with chronic myeloid leukemia (CML) in myeloid blast crisis (MBC) or lymphoid blast crisis (LBC) remains poor...
  26. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009;16:232-45 pubmed publisher
    ..until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into LBC is unknown...
  27. Naunheim M, Nahed B, Walcott B, Kahle K, Soupir C, Cahill D, et al. Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clin Neurol Neurosurg. 2010;112:575-7 pubmed publisher
    ..lymphoblastic leukemia (ALL) who presented with diffuse encephalopathy due to ICH in the setting of an acute blast crisis. The diagnosis of ALL was initially suspected, because of the hyperleukocytosis observed on presentation, then ..
  28. Ban K, Gao Y, Amin H, Howard A, Miller C, Lin Q, et al. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood. 2008;111:2904-8 pubmed publisher
    Chronic myelogenous leukemia (CML) invariably progresses to blast crisis, which represents the most proliferative phase of the disease...
  29. Sharma P, Dhingra K, Roy S, Singh T. An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia. J Pediatr Hematol Oncol. 2009;31:220-1 pubmed publisher
    ..bcr-abl positive chronic myeloid leukemia who subsequently developed a fatal AML-M6b (pure erythroleukemia) blast crisis is presented...
  30. Abrahamsson A, Geron I, Gotlib J, Dao K, Barroga C, Newton I, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A. 2009;106:3925-9 pubmed publisher
    ..from a chronic phase (CP) in hematopoietic stem cells (HSC) that harbor the BCR-ABL translocation, to blast crisis (BC), characterized by aberrant activation of beta-catenin within granulocyte-macrophage progenitors (GMP)...
  31. Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H. Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation. 2008;76:908-22 pubmed publisher
    ..It is believed that in the blast crisis (BC) terminal phase of the disease, blood-circulating blasts represent an expansion of a single CML clone...
  32. Mak D, Wang R, Schober W, Konopleva M, Cortes J, Kantarjian H, et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012;26:788-94 pubmed publisher
    ..CML), imatinib not only is inactive against quiescent CML stem cells, but also has limited activity against blast crisis (BC) CML...
  33. Peterson L, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25:761-9 pubmed publisher
    ..with MI-219-a novel compound, and consequently p53 stabilization induce chronic myeloid leukemia (CML) blast crisis cells to undergo apoptosis regardless of the presence of the T315I mutation in the BCR-ABL kinase domain...
  34. Tefferi A, Lasho T, Abdel Wahab O, Guglielmelli P, Patel J, Caramazza D, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24:1302-9 pubmed publisher
    ..The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes...
  35. van Luijn M, Chamuleau M, Thompson J, Ostrand Rosenberg S, Westers T, Souwer Y, et al. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica. 2010;95:485-93 pubmed publisher
    ..The current study investigates the role of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clinical and functional impact of the class II-associated invariant chain peptide (CLIP)...
  36. Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer H, et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev. 2007;16:503-14 pubmed
    ..FK228) in BCR/ABL-expressing cell lines and its effectiveness in imatinib-resistant cells from patients with blast crisis of CML. FK228 potently induced apoptosis of TF-1 BCR/ABL, K562, and H7 BCR/ABL cells...
  37. Melo J, Barnes D. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-53 pubmed
    ..If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood...
  38. Sengupta A, Banerjee D, Chandra S, Banerji S, Ghosh R, Roy R, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007;21:949-55 pubmed
    ..CML stem-cell compartment is dynamic as it progresses to terminal blast crisis where myeloid and lymphoid blasts fail to differentiate...
  39. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer. 2006;95:775-81 pubmed
    ..However, a significant percentage of CML patients develop resistance to imatinib and/or still progresses to blast crisis, a disease stage that is often refractory to imatinib therapy...
  40. Mak D, Schober W, Chen W, Konopleva M, Cortes J, Kantarjian H, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009;8:2509-16 pubmed publisher
    ..However, resistance evolves due to BCR-ABL mutations and other mechanisms. Furthermore, patients with blast crisis CML are less responsive and quiescent CML stem cells are insensitive to these inhibitors...
  41. Nakahara F, Sakata Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood. 2010;115:2872-81 pubmed publisher
    ..to irradiated mice, the combination of Hes1 and BCR-ABL in CMPs and GMPs caused acute leukemia resembling blast crisis of chronic myelogenous leukemia (CML), resulting in rapid death of the recipient mice...
  42. Zhao F, Mancuso A, Bui T, Tong X, Gruber J, Swider C, et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene. 2010;29:2962-72 pubmed publisher
    As chronic myeloid leukemia (CML) progresses from the chronic phase to blast crisis, the levels of BCR-ABL increase...
  43. Fereshteh M, Ito T, Kovacs J, Zhao C, Kwon H, Tornini V, et al. ?-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci U S A. 2012;109:12532-7 pubmed publisher
    ..arrestin2 preferentially leads to a severe impairment in the establishment and propagation of the chronic and blast crisis phases of chronic myelogenous leukemia (CML)...
  44. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005;157:53-61 pubmed
    ..In addition, the investigation of 10 cases of lymphoid blast crisis of CML showed significant differences in the karyotype in comparison to Ph+ ALL at diagnosis...
  45. Pear W, Miller J, Xu L, Pui J, Soffer B, Quackenbush R, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780-92 pubmed
    ..The disease in many of these mice has progressed to the development of acute lymphoma/leukemia resembling blast crisis. These results demonstrate that murine CML recapitulates important features of human CML...
  46. Nowicki M, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22:3952-63 pubmed
    ..Interestingly, CML-blast crisis cells in peripheral blood differ from those from bone marrow, indicating major changes in gene expression ..
  47. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-22 pubmed
    ..evolves from a chronic phase characterized by the Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often associated with additional chromosomal and molecular secondary changes...
  48. Honda H, Oda H, Suzuki T, Takahashi T, Witte O, Ozawa K, et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood. 1998;91:2067-75 pubmed
    ..MPD mouse showed remarkable proliferation of blast cells in the lung, which might represent an extramedullar blast crisis. The results demonstrate that the expression of p210bcr/abl in hematopoietic progenitor cells in transgenic ..
  49. Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-9 pubmed
    b>Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy...
  50. Jamieson C, Ailles L, Dylla S, Muijtjens M, Jones C, Zehnder J, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-67 pubmed
    The progression of chronic myelogenous leukemia (CML) to blast crisis is supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells, the process of self-renewal involves the beta-catenin-signaling pathway...
  51. Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355-68 pubmed
    ..We show here that, in BCR/ABL-transformed cells and CML blast crisis (CML-BC) progenitors, the phosphatase activity of the tumor suppressor PP2A is inhibited by the BCR/ABL-induced ..
  52. Notari M, Neviani P, Santhanam R, Blaser B, Chang J, Galietta A, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2006;107:2507-16 pubmed
    Altered mRNA translation is one of the effects exerted by the BCR/ABL oncoprotein in the blast crisis phase of chronic myelogenous leukemia (CML)...
  53. Marsh J, Kreis W, Barile B, Akerman S, Schulman P, Allen S, et al. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol. 1993;31:481-4 pubmed
    Eight patients, of whom four had acute myeloid leukemia (AML) and four had chronic myeloid leukemia (CML) blast crisis, were treated with a combination of cytosine arabinoside (ARA-C: 1,600 mg/m2 in three patients, 1,200 mg/m2 in five ..
  54. Sacha T, Hochhaus A, Hanfstein B, Muller M, Rudzki Z, Czopek J, et al. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res. 2003;27:1163-6 pubmed
    ..ABL-kinase and insensitivity to imatinib was detected in our patient treated with imatinib, who progressed to blast crisis. Additionally, clonal evolution could lead to BCR-ABL-independent proliferation...
  55. Yamaguchi M, Yamamoto K, Miura O. Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis. Genes Chromosomes Cancer. 2003;38:269-73 pubmed
    ..chromosome in chronic myelogenous leukemia (CML) are likely to be involved in disease progression to the blast crisis. We describe here a t(1;14)(q25;q32) as an additional chromosomal aberration in a patient with CML in ..
  56. Donato N, Wu J, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-8 pubmed
    ..Together, these results suggest that acquired STI571 resistance may be associated with BCR-ABL independence and mediated in part through overexpression of other tyrosine kinases...
  57. Sacchi S, Temperani P, Selleri L, Zucchini P, Morselli S, Vecchi A, et al. Extramedullary pleural blast crisis in chronic myelogenous leukemia: cytogenetic and molecular study. Acta Haematol. 1990;83:198-202 pubmed
  58. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-58 pubmed
    The arrest of differentiation is a feature of both chronic myelogenous leukemia cells in myeloid blast crisis and myeloid precursors that ectopically express the p210BCR-ABL oncoprotein; however, its underlying mechanisms remain poorly ..
  59. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-17 pubmed
    ..The chronic period of the disease progresses to a fatal blast crisis characterized by a clonal expansion of undifferentiated cells...